Heritability of Alzheimer's disease–related plasma biomarkers in the Amish population

Read full text
Authors: Ping Wang, Yeunjoo E. Song, Audrey Lynn, Kristy Miskimen, Alex Gulyayev, Michael B. Prough, Daniel A. Dorfsman, Renee A. Laux, Sarada L. Fuzzell, Sherri D. Hochstetler, Andrew F. Zaman, Larry D. Adams
+14 more Laura J. Caywood, Jason E. Clouse, Sharlene D. Herington, Patrice Whitehead, Yining Liu, Noel Moore, Paula Ogrocki, Alan J. Lerner, Anthony J. Griswold, Jeffery M. M Vance, Michael L. Cuccaro, William K. Scott, Margaret A. Pericak‐Vance, Jonathan L. Haines
Cited by: 1
References: 31

Abstract

Abstract INTRODUCTION Plasma biomarkers for Alzheimer's disease (AD) hold promise for disease diagnosis and prediction, yet their genetic underpinnings remain under explored. METHODS We measured plasma amyloid beta (Aβ)40, Aβ42, Aβ42/Aβ40, total tau (t‐tau), phosphorylated tau 181 (p‐tau181), Aβ42/t‐tau, Aβ42/p‐tau181, neurofilament light chain, and glial fibrillary acidic protein in the Midwestern Amish. Pedigree‐based heritability () was estimated from multigenerational pedigrees, and single nucleotide polymorphism (SNP)–based heritability () was derived from SNPs. RESULTS Among all Amish individuals, additive genetic effects explained 11.1% to 36.6% of biomarker variances. estimates were consistently lower, ranging from 6.7% to 28.7%. The heritability of these biomarkers in subgroups of cognitively normal individuals and apolipoprotein E ε4 non‐carriers yielded similar results. DISCUSSION Plasma biomarkers such as Aβ, t‐tau, and p‐tau181 are moderately heritable in the Amish, underscoring the impact of genetic determinants of plasma biomarkers associated with AD.

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research Prion Diseases and Protein Misfolding Alzheimer's disease research and treatments

Publication details

Journal / source
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
Publisher
Wiley
Volume
18
Issue
2
Pages
e70388–e70388
Publication date
1 April 2026
Language
EN